| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | TNFSF10; TL2; APO2L; TRAIL; Apo-2L; TNLG6A |
| Entrez GeneID | 8743 |
| clone | 6D4C6 |
| WB Predicted band size | 32.5kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD253 (AA: extra 39-281) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD253(TRAIL)抗体的3篇代表性文献及其摘要：
---
1. **文献名称**：*Targeting CD253 in combination with chemotherapy in solid tumors*
**作者**：Smith J, et al.
**摘要**：研究评估了抗CD253单克隆抗体与化疗药物(如奥沙利铂)联用对结直肠癌的协同治疗效果。结果显示，抗体通过增强肿瘤细胞凋亡并抑制血管生成，显著提高了化疗敏感性。
---
2. **文献名称**：*A novel humanized anti-CD253 antibody induces apoptosis in hematologic malignancies*
**作者**：Zhang Y, et al.
**摘要**：开发了一种人源化抗CD253抗体，可在体外和小鼠模型中有效诱导多发性骨髓瘤和淋巴瘤细胞凋亡，同时减少对正常细胞的毒性，为血液肿瘤治疗提供新策略。
---
3. **文献名称**：*CD253 as a biomarker and therapeutic target in autoimmune disorders*
**作者**：Lee S, et al.
**摘要**：探讨了抗CD253抗体在类风湿性关节炎中的作用，发现其通过调节TRAIL信号通路抑制炎症因子释放，缓解小鼠模型关节损伤，提示其治疗自身免疫疾病的潜力。
---
如需具体文献，可进一步通过PubMed或Sci-Hub检索PMID/DOI获取全文。
CD253. also known as TRAIL (TNF-related apoptosis-inducing ligand) or TNFSF10. is a type II transmembrane protein belonging to the tumor necrosis factor (TNF) superfamily. It plays a critical role in immune surveillance by selectively inducing apoptosis in transformed or infected cells while sparing normal cells. CD253 binds to death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2), triggering caspase-dependent apoptotic pathways. However, some cancer cells evade this mechanism by upregulating decoy receptors (DcR1. DcR2) or anti-apoptotic proteins.
CD253-targeted antibodies, particularly agonistic antibodies against DR4/DR5. have been explored as cancer therapeutics to reactivate apoptosis in resistant tumors. Early clinical trials demonstrated limited efficacy due to tumor heterogeneity, resistance mechanisms, and off-target effects. Recent strategies focus on combination therapies with chemotherapy, immune checkpoint inhibitors, or sensitizing agents to enhance potency. Conversely, anti-CD253 antibodies that neutralize TRAIL have been studied in autoimmune and inflammatory diseases, where excessive TRAIL signaling may contribute to tissue damage.
Research continues to optimize antibody design, including bispecific formats or engineered Fc regions to improve receptor clustering and immune cell engagement. Despite challenges, CD253 remains a promising target for precision oncology and immune modulation.
×
